Nasdaq Volume, page-3

ASX/NASDAQ ANNOUNCEMENT Benitec Biopharma to Present at 30th Annual ROTH Conference

Sydney Australia, 13 March 2018: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced that Greg West, Chief Executive Officer, will present at the 30th Annual ROTH Capital Partners Conference in Dana Point, CA. Details of the presentation are as follows: Date: Tuesday 13 March 2018 Time: 1:00pm Location: Salon 3, Ritz-Carlton Laguna Niguel The presentation will provide a corporate overview, including highlights on recent advancements in the Company’s pipeline programs, as well as the outlook for 2018. The presentation will be lodged with the ASX and available via the investor relations section of the Company’s website at www.benitec.com following the live presentation. For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Australia Investor Relations United States Investor Relations Market Eye Orla Keegan Director Tel: +61 (2) 8097 1201 Email: [email protected] M Group Strategic Communications Jay Morakis Managing Director Tel: +1 212.266.0190 Email: [email protected]

About Benitec Biopharma Limited: Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including OPMD, head & neck squamous cell carcinoma, retinal based diseases such as wet age-related macular degeneration, and hepatitis B.

Safe Harbor Statement: This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in this ASX/Nasdaq announcement are subject to risks and uncertainties relating to the difficulties in Benitec’s plans to develop and commercialise its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec’s product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results